Title |
nab-Paclitaxel dose and schedule in breast cancer
|
---|---|
Published in |
Breast Cancer Research, June 2015
|
DOI | 10.1186/s13058-015-0587-y |
Pubmed ID | |
Authors |
Miguel Martín |
Abstract |
nab-Paclitaxel is approved for the treatment of metastatic breast cancer on an every-3-week schedule based on positive findings from a pivotal phase III trial in which nab-paclitaxel 260 mg/m(2) every 3 weeks was superior to solvent-based paclitaxel 175 mg/m(2) every 3 weeks for the primary endpoint of overall response rate (33 % vs 19 %; P = 0.001). Subsequently, a number of trials have examined different schedules, doses, and combinations in efforts to optimize nab-paclitaxel-based therapy for metastatic and early-stage breast cancer. The goal of this review is to evaluate the clinical experiences to date with nab-paclitaxel as a single agent or in combination with targeted agents in different treatment settings - with a focus on the feasibility of administration, adverse event profile, and standard efficacy endpoints, such as overall survival, progression-free survival, overall response rate, and pathologic complete response rate. In general, weekly dosing during the first 3 of 4 weeks appears to achieve the best clinical benefit in both the metastatic and early-stage settings. Furthermore, the data suggest that high doses of nab-paclitaxel, such as 150 mg/m(2) during first 3 of 4 weeks or 260 mg/m(2) every 2 weeks, may be more feasible and appropriate for treatment of early-stage disease compared with metastatic disease. Intense regimens of nab-paclitaxel may not be the best treatment approach for unselected patients with metastatic breast cancer, but may suit a subset of patients for whom immediate disease control is required. The growing number of nab-paclitaxel trials in breast cancer will lead to greater refinements in tailoring therapy to patients based on their individual disease and patient characteristics. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Spain | 1 | 2% |
Portugal | 1 | 2% |
Unknown | 54 | 96% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Other | 7 | 13% |
Student > Bachelor | 7 | 13% |
Student > Ph. D. Student | 6 | 11% |
Student > Master | 6 | 11% |
Student > Postgraduate | 5 | 9% |
Other | 10 | 18% |
Unknown | 15 | 27% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 15 | 27% |
Pharmacology, Toxicology and Pharmaceutical Science | 7 | 13% |
Biochemistry, Genetics and Molecular Biology | 6 | 11% |
Agricultural and Biological Sciences | 3 | 5% |
Unspecified | 2 | 4% |
Other | 6 | 11% |
Unknown | 17 | 30% |